Åse Bjorvatn SævikSørlandet Hospital | SSHF
Åse Bjorvatn Sævik
MD, PhD
About
15
Publications
3,385
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
91
Citations
Publications
Publications (15)
Objective
Increased prevalence of cardiovascular disease has been reported in autoimmune Addison’s disease (AAD), but pathomechanisms are poorly understood.
Design
Cross-sectional study.
Methods
We compared serum levels of 177 cardiovascular and inflammatory biomarkers in 43 patients with AAD at > 18-hour glucocorticoid withdrawal and 43 matched...
Disclosure: Å.B. Sævik: None. G. Ueland: None. A. Åkerman: None. P. Methlie: None. M. Quinkler: None. A. Jørgensen: None. C. Höybye: None. A.W. Debowska: None. B. Nedrebø: None. A. Dahle: None. S. Carlsen: None. A.E. Tomkowicz: None. S.T. Sollid: None. I. Nermoen: None. K. Grønning: None. P.M. Dahlqvist: None. G. Grimnes: None. J. Skov: None. T. Fi...
Objective
To map inflammatory biomarkers in patients with autonomous cortisol secretion (ACS), and overt Cushing syndrome (CS).
Method
Observational study including serum from prospectively included patients with ACS (n = 63), adrenal CS (n = 2), pituitary CS (n = 8), and healthy subjects (n = 120). Serum samples were analysed for 92 inflammatory...
Purpose:
Residual adrenocortical function, RAF, has recently been demonstrated in one-third of patients with autoimmune Addison's disease (AAD). Here, we set out to explore any influence of RAF on the levels of plasma metanephrines and any changes following stimulation with cosyntropin.
Methods:
We included 50 patients with verified RAF and 20 p...
Background
Patients with primary adrenal insufficiency (PAI) suffer reduced quality of life (QoL), but comparisons with large-scale normative data are scarce. The clinical characteristics associated with reduced QoL are largely unknown.
Methods
Cross-sectional data on clinical characteristics and QoL scores from 494 patients were included. QoL was...
Objective: Deciding the optimal doses of glucocorticoid (GC) replacement treatment in autoimmune Addison’s disease (AAD) is impeded by the lack of reliable biomarkers. This frequently results in over-treatment, with alarming and persistent side-effects, or under-replacement, which could be fatal. There is a need to think new in the quest for robust...
Background
No reliable biomarkers exist to guide glucocorticoid (GC) replacement treatment in autoimmune Addison’s disease (AAD), leading to overtreatment with alarming and persistent side-effects or undertreatment, which could be fatal.
Objective
To explore changes in gene expression following different GC replacement doses as a means of identify...
Context
Appropriate management of adrenal insufficiency (AI) in pregnancy can be challenging due to the rarity of the disease and lack of evidence-based recommendations to guide glucocorticoid- and mineralocorticoid dosage adjustment.
Objective
Multi-center survey on current clinical approaches in managing AI during pregnancy.
Design
Retrospectiv...
Context
Contrary to current dogma, growing evidence suggests that some patients with autoimmune Addison’s disease (AAD) produce corticosteroids even years after diagnosis.
Objective
Determine frequencies and clinical features of residual corticosteroid production in patients with AAD.
Design
Two-staged, cross-sectional clinical study in 17 center...
Background:
Early detection of autoimmune Addison's disease (AAD) is important as delay in diagnosis may result in a life-threatening adrenal crisis and death. The classical clinical picture of untreated AAD is well-described, but methodical investigations are scarce.
Objective:
Perform a retrospective audit of patient records with the aim of id...
Questions
Questions (2)
I am doing a study on how a certain exposure may affect (change) biomarker profiles in human serum, i.e. at baseline compared to 1 hour after the exposure. In order to detect any change, I assume the biomarker half-lives should be short (at least less than 1 hour). Unfortunately, I struggle to find reliable and comprehensive sources (ideally a database) on half-lives of proteins/ biomarkers in human serum. (The manufacturer does not have this kind of information either).
I would be immensely grateful for any suggestions on how to find this kind of information! (without having to perform half-life experiments myself for the 150-200 proteins of interest)
Hi,
I have biomarker data given in log2-scale, and I am looking into different approaches on how to present the results (differences between two groups). I have seen a paper (with similar data) present the difference as fold change, i.e. fold change of 1.5 for biomarker A for group X relative to group Y. However, I wonder whether this is an appropriate approach, as the difference between the given values already describe a ratio, i.e. a mean difference of 1 unit represents a doubling of protein concentration (as the unit is a log2 scale). In other words, calculating the fold change would be more appropriate if I had absolute values?
